Clonal endothelial cells produce humoral factors that inhibit osteoclast-like cell formation in vitro

Endocrine Journal

Volumn 49, Issue 4, 2002, Pages 439-447

  Chikatsu, Noriko ^a   Takeuchi, Yasuhiro ^a   Fukumoto, Seiji ^a   Yano, Kazuki ^b   Fujita, Naoya ^c   Tsuruo, Takashi ^c   Fujita, Toshiro ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b SNOW BRAND MILK PRODUCTS CO LTD   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

Bone marrow cell; Endothelial cell; Osteoclast; Osteoprotegerin; RANKL

Indexed keywords

CALCITRIOL; COLONY STIMULATING FACTOR 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PROSTAGLANDIN E2; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ARTICLE; BONE MARROW CULTURE; CLONE; CONTROLLED STUDY; CULTURE MEDIUM; ENDOTHELIUM CELL; GENE EXPRESSION; IN VITRO STUDY; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; VASCULAR ENDOTHELIUM;

ANIMALS; AORTA; BONE AND BONES; BRAIN; CARRIER PROTEINS; CELL DIVISION; CELLS, CULTURED; CLONE CELLS; ENDOTHELIUM; ENDOTHELIUM, VASCULAR; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; OSTEOCLASTS; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; STEM CELLS;

EID: 0036692359     PISSN: 09188959     EISSN: None     Source Type: Journal    
DOI: 10.1507/endocrj.49.439     Document Type: Article

References (40)

1. Anatomy and ultrastructure of bone
2. The mechanism of coupling: A role for the vasculature
3. VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation
4. Induction of vascular endothelial growth factor expression by prostaglandin E2 and E1 in osteoblasts
5. Increase of vascular endothelial growth factor mRNA expression by 1,25-dihydroxyvitamin D3 in human osteoblast-like cells
6. Nitric oxide acts in conjunction with proinflammatory cytokines to promote cell death in osteoblasts
7. Interaction between nitric oxide synthase and cyclooxygenase pathways in osteoblastic MC3T3-E1 cells
8. Endothelin-1 I is a potent regulator of human bone cell metabolism in vitro
9. 3 on osteoblasts are enhanced by vascular endothelial growth factor produced by osteoblasts and by growth factors produced by endothelial cells
10. Endothelin inhibits osteoclastic bone resorption by a direct effect on cell motility: Implications for the vascular control of bone resorption
11. Osteoclastic inhibition: An action of nitric oxide not mediated by cyclic GMP
12. Production of interleukin-11 in bone-derived endothelial cells and its role in the formation of osteolytic bone metastasis
13. Reduced expression of interleukin-11 in bone marrow stromal cells of senescence-accelerated mice (SAMP6): Relationship to osteopenia with enhanced adipogenesis
14. Osteoclast-like cell formation and its regulation by osteotropic hormones in mouse bone marrow cultures
15. Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: Increased serum concentrations in postmenopausal women with osteoporosis
16. Osteoclast precursors as leukocytes: Importance of the area code
17. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL
18. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis
19. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand
20. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis
21. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin
22. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density
23. TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling
24. Requirement for NF-κB in osteoclast and B-cell development
25. Required and nonessential functions of nuclear factor-κB in bone cells
26. Interleukins in the control of osteoclast differentiation
27. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families
28. Interleukin-18 (interferon-γ-inducing factor) is produced by osteoblasts and acts via granulocyte/macrophage colony-stimulating factor and not via interferon-γ to inhibit osteoclast formation
29. Human blood-mobilized hematopoietic precursors differentiate into osteoclasts in the absence of stromal cells
30. Osteoclast differentiation factor (ODF) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures
31. Role of the endothelial cell in osteoclast control: New perspectives
32. Interleukin-11: A new cytokine critical for osteoclast development
33. Effect of surgical menopause and estrogen replacement on cytokine release from human blood mononuclear cells
34. Constitutive up-regulation of integrin-mediated adhesion of tumor-infiltrating lymphocytes to osteoblasts and bone marrow-derived stromal cells
35. Interleukin 1 induces multinucleation and bone-resorbing activity of osteoclasts in the absence of osteoblasts/stromal cells
36. Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction
37. Recombinant human IL-11 attenuates the inflammatory response through down-regulation of proinflammatory cytokine release and nitric oxide production
38. Important immunoregulatory role of interleukin-11 in the inflammatory process in rheumatoid arthritis
39. Optimizing therapy for inflammatory bowel disease
40. Cytokines in inflammatory bowel disease